Tinengotinib
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment[1][2].
Product Specifications
CAS Number
2230490-29-4
Product Name Alternative
TT 00420
UNSPSC
12352005
Target
Aurora Kinase; FGFR; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tinengotinib.html
Purity
99.57
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
ClC1=C(C2=NC3=C(C)NN=C3NC4=C2C=NC(N5CCOCC5)=C4)C=CC=C1
Molecular Formula
C20H19ClN6O
Molecular Weight
394.86
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Aurora A; Aurora B
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD35 (C3 binding Protein, C3b/C4b receptor, C3BR, C4BR, Complement Component (3b/4b) receptor 1 including Knops blood group system, Complement receptor type 1, KN, Knops blood group antigen, CR1) (Biotin)